| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 370 | 0 | 0 | 0 |
| Sales Growth | -100.00% | unch | unch | unch | unch |
| Net Income | -20,140 | -7,370 | 0 | 0 | 0 |
| Net Income Growth | -173.27% | unch | unch | unch | unch |
Phaserx Inc (PZRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash.